231 related articles for article (PubMed ID: 29902578)
1. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer.
Fararjeh AS; Tu SH; Chen LC; Liu YR; Lin YK; Chang HL; Chang HW; Wu CH; Hwang-Verslues WW; Ho YS
Hum Pathol; 2018 Oct; 80():219-230. PubMed ID: 29902578
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
3. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
4. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
5. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.
Liu L; Chi Y; Chen J; Xue J; Deng L; Huang N; Shao J; Wu J
Sci Rep; 2017 Sep; 7(1):12382. PubMed ID: 28959047
[TBL] [Abstract][Full Text] [Related]
7. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
8. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
9. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
10. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
[TBL] [Abstract][Full Text] [Related]
12. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma.
Hashiguchi T; Miyoshi H; Nakashima K; Yokoyama S; Matsumoto R; Murakami D; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Hum Pathol; 2017 May; 63():157-164. PubMed ID: 28322854
[TBL] [Abstract][Full Text] [Related]
15. Higher levels of GATA3 predict better survival in women with breast cancer.
Yoon NK; Maresh EL; Shen D; Elshimali Y; Apple S; Horvath S; Mah V; Bose S; Chia D; Chang HR; Goodglick L
Hum Pathol; 2010 Dec; 41(12):1794-801. PubMed ID: 21078439
[TBL] [Abstract][Full Text] [Related]
16. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
18. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
19. Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer.
Min KW; Kim DH; Do SI; Chae SW; Kim K; Sohn JH; Pyo JS; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kim EK; Kwon MJ; Seo J; Moon KM
Virchows Arch; 2016 Apr; 468(4):409-16. PubMed ID: 26719157
[TBL] [Abstract][Full Text] [Related]
20. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
